Jerry Jeffrey

1.2k total citations
25 papers, 839 citations indexed

About

Jerry Jeffrey is a scholar working on Virology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Jerry Jeffrey has authored 25 papers receiving a total of 839 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Virology, 18 papers in Infectious Diseases and 7 papers in Molecular Biology. Recurrent topics in Jerry Jeffrey's work include HIV Research and Treatment (21 papers), HIV/AIDS drug development and treatment (18 papers) and Biochemical and Molecular Research (6 papers). Jerry Jeffrey is often cited by papers focused on HIV Research and Treatment (21 papers), HIV/AIDS drug development and treatment (18 papers) and Biochemical and Molecular Research (6 papers). Jerry Jeffrey collaborates with scholars based in United States, United Kingdom and Japan. Jerry Jeffrey's co-authors include Brian A. Johns, Lishan Su, Scott A. Foster, Jason G. Weatherhead, Edward P. Garvey, James B. Thompson, Wayne H. Miller, Scott H. Allen, Ian T.D. Petty and William Gillette and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Clinical Infectious Diseases.

In The Last Decade

Jerry Jeffrey

24 papers receiving 822 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jerry Jeffrey United States	17	421	362	266	202	158	25	839
Elena Gustchina United States	15	502 1.2×	395 1.1×	317 1.2×	119 0.6×	79 0.5×	19	869
Carol Lackman-Smith United States	14	330 0.8×	307 0.8×	278 1.0×	83 0.4×	62 0.4×	22	791
Lilia M. Babé United States	16	445 1.1×	467 1.3×	418 1.6×	83 0.4×	119 0.8×	25	964
Anna Knezevich Italy	14	409 1.0×	288 0.8×	617 2.3×	117 0.6×	110 0.7×	20	1.1k
Zhenlong Liu China	15	302 0.7×	220 0.6×	326 1.2×	307 1.5×	45 0.3×	48	854
Shigeyoshi Harada Japan	17	467 1.1×	404 1.1×	286 1.1×	156 0.8×	59 0.4×	42	706
John G. Julias United States	17	594 1.4×	629 1.7×	452 1.7×	117 0.6×	104 0.7×	23	997
Elizabeth Wardrop Canada	10	246 0.6×	232 0.6×	211 0.8×	63 0.3×	76 0.5×	10	578
Ewald M. Wondrak United States	18	635 1.5×	605 1.7×	392 1.5×	67 0.3×	161 1.0×	24	947
D. Reymen Belgium	13	255 0.6×	260 0.7×	182 0.7×	87 0.4×	93 0.6×	18	709

Countries citing papers authored by Jerry Jeffrey

Since Specialization

Citations

This map shows the geographic impact of Jerry Jeffrey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerry Jeffrey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerry Jeffrey more than expected).

Fields of papers citing papers by Jerry Jeffrey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerry Jeffrey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerry Jeffrey. The network helps show where Jerry Jeffrey may publish in the future.

Co-authorship network of co-authors of Jerry Jeffrey

This figure shows the co-authorship network connecting the top 25 collaborators of Jerry Jeffrey. A scholar is included among the top collaborators of Jerry Jeffrey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerry Jeffrey. Jerry Jeffrey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Underwood, Mark, José Castillo‐Mancilla, Lesley Kahl, et al.. (2025). Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile. Clinical Infectious Diseases. 81(3). 510–520.

Spinner, Christoph D., Franco Felizarta, Giuliano Rizzardini, et al.. (2022). Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254. Clinical Infectious Diseases. 75(5). 786–794. 15 indexed citations

Johnson, Mark, Roxanne C. Jewell, Amanda Peppercorn, et al.. (2018). The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects. Pharmacology Research & Perspectives. 6(4). e00408–e00408. 16 indexed citations

Tang, Jun, Stacey A. Jones, Jerry Jeffrey, et al.. (2017). Discovery of a novel and potent class of anti-HIV-1 maturation inhibitors with improved virology profile against gag polymorphisms. Bioorganic & Medicinal Chemistry Letters. 27(12). 2689–2694. 19 indexed citations

Gupta, Kushol, Scott Sherrill-Mix, Young Sun Hwang, et al.. (2016). Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase. PLoS Biology. 14(12). e1002584–e1002584. 52 indexed citations

Tsao, Li-Chung, Haitao Guo, Jerry Jeffrey, James A. Hoxie, & Lishan Su. (2016). CCR5 interaction with HIV-1 Env contributes to Env-induced depletion of CD4 T cells in vitro and in vivo. Retrovirology. 13(1). 22–22. 12 indexed citations

Johns, Brian A., Takashi Kawasuji, Jason G. Weatherhead, et al.. (2014). Naphthyridinone (NTD) integrase inhibitors 4. Investigating N1 acetamide substituent effects with C3 amide groups. Bioorganic & Medicinal Chemistry Letters. 24(14). 3104–3107. 5 indexed citations

Johns, Brian A., Takashi Kawasuji, Jason G. Weatherhead, et al.. (2012). Naphthyridinone (NTD) integrase inhibitors: N1 Protio and methyl combination substituent effects with C3 amide groups. Bioorganic & Medicinal Chemistry Letters. 23(2). 422–425. 13 indexed citations

Johns, Brian A., Takashi Kawasuji, Jason G. Weatherhead, et al.. (2011). Combining symmetry elements results in potent naphthyridinone (NTD) HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(21). 6461–6464. 6 indexed citations

10.

Zhang, Liguo, Qi Jiang, Guangming Li, et al.. (2011). Efficient infection, activation, and impairment of pDCs in the BM and peripheral lymphoid organs during early HIV-1 infection in humanized rag2−/−γ C−/− mice in vivo. Blood. 117(23). 6184–6192. 37 indexed citations

11.

Tilton, John C., Heather Amrine‐Madsen, Kathryn M. Kitrinos, et al.. (2010). HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for Entry. AIDS Research and Human Retroviruses. 26(1). 13–24. 44 indexed citations

12.

Johns, Brian A., Jason G. Weatherhead, Scott H. Allen, et al.. (2009). The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore. Bioorganic & Medicinal Chemistry Letters. 19(6). 1802–1806. 94 indexed citations

13.

Sivaraman, Vijay, Liguo Zhang, Eric G. Meissner, Jerry Jeffrey, & Lishan Su. (2009). The Heptad Repeat 2 Domain Is a Major Determinant for Enhanced Human Immunodeficiency Virus Type 1 (HIV-1) Fusion and Pathogenicity of a Highly Pathogenic HIV-1 Env. Journal of Virology. 83(22). 11715–11725. 19 indexed citations

14.

Johns, Brian A., Jason G. Weatherhead, Scott H. Allen, et al.. (2009). 1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position. Bioorganic & Medicinal Chemistry Letters. 19(6). 1807–1810. 71 indexed citations

15.

Jiang, Qi, Liguo Zhang, Rui Wang, et al.. (2008). FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2−/−γC−/− mice in vivo. Blood. 112(7). 2858–2868. 88 indexed citations

16.

Borroto–Esoda, Katyna, Florence Myrick, Joy Y. Feng, Jerry Jeffrey, & Phillip A. Furman. (2004). In Vitro Combination of Amdoxovir and the Inosine Monophosphate Dehydrogenase Inhibitors Mycophenolic Acid and Ribavirin Demonstrates Potent Activity against Wild-Type and Drug-Resistant Variants of Human Immunodeficiency Virus Type 1. Antimicrobial Agents and Chemotherapy. 48(11). 4387–4394. 29 indexed citations

17.

Jeffrey, Jerry, et al.. (2003). Dioxolane Guanosine 5′-Triphosphate, an Alternative Substrate Inhibitor of Wild-type and Mutant HIV-1 Reverse Transcriptase. Journal of Biological Chemistry. 278(21). 18971–18979. 29 indexed citations

18.

Furman, Phillip A., Jerry Jeffrey, Laura L. Kiefer, et al.. (2001). Mechanism of Action of 1-β- d -2,6-Diaminopurine Dioxolane, a Prodrug of the Human Immunodeficiency Virus Type 1 Inhibitor 1-β- d -Dioxolane Guanosine. Antimicrobial Agents and Chemotherapy. 45(1). 158–165. 60 indexed citations

19.

Gillette, William, et al.. (1998). Genetic Determinants of Host-Specificity in Bipartite Geminivirus DNA A Components. Virology. 251(2). 361–369. 14 indexed citations

20.

Gillette, William, et al.. (1996). Host and Viral Factors Determine the Dispensability of Coat Protein for Bipartite Geminivirus Systemic Movement. Virology. 218(1). 264–268. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact